Table 1.
Clinicopathologic factors affecting progression-free and overall survivals in all 360 patients with advanced-stage ovarian cancer.
| Characteristics | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P value | Adjusted HR | 95% CI | P value | |
| Progression-free survival | ||||||
| ≥53 years | 1.04 | 0.82–1.32 | 0.74 | — | — | — |
| Stage IV disease | 1.27 | 0.95–1.69 | 0.11 | — | — | — |
| Grade 3 disease | 1.11 | 0.80–1.53 | 0.53 | — | — | — |
| Nonserous histology | 1.26 | 0.95–1.67 | 0.11 | — | — | — |
| No neoadjuvant chemotherapy | 1.62 | 1.19–2.20 | <0.01 | 1.84 | 1.18–2.87 | <0.01 |
| ≤6 cycles of adjuvant chemotherapy | 1.03 | 0.81–1.32 | 0.81 | — | — | — |
| Suboptimal debulking surgery | 1.54 | 1.21–1.96 | <0.01 | 1.71 | 1.22–2.39 | <0.01 |
| Underweight after treatment | 1.25 | 0.80–1.93 | 0.33 | — | — | — |
| Overall survival | ||||||
| ≥53 years | 1.12 | 0.79–1.58 | 0.52 | — | — | — |
| Stage IV disease | 1.21 | 0.80–1.84 | 0.36 | — | — | — |
| Grade 3 disease | 1.21 | 0.75–1.93 | 0.44 | — | — | — |
| Nonserous histology | 1.58 | 1.07–2.33 | 0.02 | — | — | — |
| No neoadjuvant chemotherapy | 1.65 | 1.08–2.54 | 0.02 | 1.88 | 1.28–2.77 | <0.01 |
| ≤6 cycles of adjuvant chemotherapy | 1.16 | 0.82–1.64 | 0.42 | — | — | — |
| Suboptimal debulking surgery | 1.49 | 1.05–2.11 | 0.03 | 1.67 | 1.23–2.28 | <0.01 |
| Underweight after treatment | 2.01 | 1.13–3.58 | 0.02 | 2.29 | 1.08–4.85 | 0.03 |